Related Experiment Video
Updated: Jun 10, 2026

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
Published on: September 20, 2020
Experience With Performing Rheocarna Therapy via the Single-Needle Method for Treatment of Chronic Limb-Threatening
Yasutaka Yamauchi1,2, Rie Tanaka3, Reona Kawahira3
1Cardiovascular Center, Takatsu General Hospital, Kawasaki, Kanagawa, Japan.
Introduction:
This study investigated the safety and efficacy of single-needle Rheocarna therapy for chronic limb-threatening ischemia (CLTI) with wounds.
Methods:
Six patients with CLTI involving ulcers unresponsive to revascularization underwent single-needle Rheocarna treatment. Changes in mean low-density lipoprotein cholesterol (LDL-C), fibrinogen, C-reactive protein (CRP), white blood cell (WBC) count, platelet count, blood flow, and wound improvement were compared between treatment initiation and completion.
Results:
The treatment never required discontinuation due to in-circuit coagulation or hypotension, and its safety was confirmed. After 10 treatment sessions, LDL-C and fibrinogen removal rates were 24.3% and 24.4%, respectively. Platelet, WBC, and CRP values did not change significantly over time. Blood flow increased during treatment and posttreatment. All patients experienced wound improvement and favorable clinical outcomes.
Conclusion:
Single-needle Rheocarna therapy is effective for wound healing in CLTI. If this method applies to nondialysis patients without arteriovenous fistulas, indications for Rheocarna therapy will likely expand.
Related Concept Videos
Peripheral Artery Disease III: Interprofessional Care
Local Anesthetics: Clinical Application as Intravenous Regional Anesthesia
One of the advantages of...
Peripheral Artery Disease IV: Nursing Management
